Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

Diabetic Foot Clinical Trial

Official title:

An Open-Label Trial to Assess the Clinical Effectiveness of Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05087758
• Other study ID #: CR-21-001
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2022
• Est. completion date: March 30, 2024

Study information

• Verified date: May 2023
• Source: LifeNet Health
• Contact: Barry Saxton, PA-C
• Phone: 404 314 4903
• Email: barry_saxton[@]lifenethealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:

1. Be male or female, between 21 and 80 years of age at the time of consent

2. For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit

3. Have a full-thickness wound of the lower extremity

4. Have a single target ulcer

5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm

6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

• Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue

• Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis

7. Have an absence of infection based on Infectious Disease Society of America criteria

8. Have an adequate circulation to the affected lower extremity, defined as at least one these criteria:

• Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg

• Ankle-brachial index (ABI) greater than 0.75

• At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries

9. Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements

10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments

11. Have provided written authorization for use and disclosure of protected health information

12. Have a life expectancy of greater than 6 months

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

1. Be pregnant or lactating

2. Have a wound that decreased in size =50% between the Screening and Baseline Visits

3. Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit

4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening

5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin

6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®

7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit

8. Need for any additional concomitant dressing material other than the ones approved for this study

9. Have clinical signs of an infection at the study ulcer site

10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast)

11. Have a known or suspected disease of the immune system

12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease

13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the baseline visit

14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement

15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit

16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening

17. Have evidence of active Charcot disease

18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening

19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot

20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Related Conditions & MeSH terms

• Diabetic Foot
• Foot Ulcer
• Lower Extremity Wound

Intervention

Other:
• Matrion
Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
• Conventional Care Wound Management
Advanced wound care with debridement and dressings

Locations

Country	Name	City	State
United States	Albuquerque Associated Podiatrists	Albuquerque	New Mexico
United States	Center for Clinical Research, INC	Carmichael	California
United States	Limb Preservation Platform, INC	Fresno	California
United States	Doctors Research Network	Miami	Florida
United States	Purvis-Moyer Foot and Ankle Center	Rocky Mount	North Carolina
United States	ILD Research Center	San Diego	California
United States	Center for Clinical Research, INC	San Francisco	California
United States	Compass Medical Research Center, LLC	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
LifeNet Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wound Healing	Proportion of chronic DFUs that have achieved complete wound closure	12 weeks
Secondary	Speed of Wound Closure	Time to wound closure measured from the baseline visit to the termination visit	12 weeks
Secondary	Wound Area	Change in wound area over time	12 weeks
Secondary	Infection	Rate of wound infection	12 weeks
Secondary	Reoccurrence	Rate of reoccurrence of wound post treatment	6 months post termination visit
Secondary	Grafts Used	Average number of Matrion grafts used per subject	12 weeks
Secondary	Incidence of Treatment Emergent Adverse Events	Collection of adverse events, including changes in vital signs, ABI, and physical exams	12 weeks